Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | PKM | P14618 | 2/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500873 | 0.91 | KMT2A (1.00) | KMT2APKMTSHRSMN1; SMN2HPGD | |
| SCHEMBL29195354 | 0.82 | KMT2A (0.82) | KMT2APKMTSHRSMN1; SMN2HPGD | |
| SCHEMBL4597260 | 0.77 | ALDH1A1 (0.76) | KMT2APKMTSHRSMN1; SMN2HPGD | |
| SCHEMBL2592761 | 0.77 | KMT2A (0.74) | KMT2APKMTSHRSMN1; SMN2HPGD | |
| SCHEMBL11742920 | 0.77 | TSHR (0.74) | KMT2APKMTSHRSMN1; SMN2HPGD | |
| SCHEMBL23221842 | 0.76 | TDP1 (0.58) | KMT2APKMTSHRSMN1; SMN2HPGD | |
| SCHEMBL24252541 | 0.75 | CD274 (0.64) | KMT2APKMTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL31066579 | 0.75 | CYP2D6 (0.58) | KMT2APKMTSHRSMN1; SMN2CMA1 | |
| SCHEMBL4013498 | 0.75 | CMA1 (0.55) | KMT2APKMTSHRSMN1; SMN2HPGD | |
| SCHEMBL2258501 | 0.75 | KMT2A (0.70) | KMT2APKMTSHRSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | KMT2A 1991/4885PKM 619/4885TSHR 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.